Details

Project TitleProdrugs of Fluorinated Mevalonates to Inhibit the Mevalonate Pathway of Streptococcus pneumoniae
Track Code2012-018
Short Description

Pro-drug antibiotic candidates for the treatment of penicillin-resistant Streptococcus pneumoniae infections.

#therapeutics #smallmolecule #pulmonary #infectiousdisease

Abstract

Infection by the Streptococcus pneumoniae bacterium is a significant health risk, particularly for children in developing countries. The incidence of strains of the microbe that are resistant to penicillin and other classic treatments has been on the rise since the mid-1990s. New target pathways for the development of antibiotic treatments are sorely needed. The mevalonate pathway has recently been identified as a useful pathway for development of new drugs, but treatment candidates to date have been limited by metabolic effects after administration to an organism. Northwestern researchers have developed "prodrugs" – chemically modified molecules that transform into pharmacologically active entities within an organism – that target this essential pathway. These molecules have been tested in human plasma and may prove very useful in attempts to combat penicillin-resistant strains of Streptococcus pneumoniae.

 
Tagspulmonary, THERAPEUTICS: small molecule, THERAPEUTICS: infectious disease
 
Posted DateMar 20, 2013 3:19 PM

Inventor(s)

Richard B. Silverman*
Soosung Kang

Mizuki Watanabe

Applications

Treatment of Streptococcus pneumoniae, including penicillin-resistant strains

Advantages

  • Combats bacteria resistant to current antibiotics
  • Overcomes metabolic limitations presented by other drug candidates

Publications

IP Status

A patent application has been filed.

Contact Information

Vara Josyula, PhD
Invention Manager  
(p) 847.491.4456

(e) vara.josyula@northwestern.edu